AR119210A1 - DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR - Google Patents

DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Info

Publication number
AR119210A1
AR119210A1 ARP200101749A ARP200101749A AR119210A1 AR 119210 A1 AR119210 A1 AR 119210A1 AR P200101749 A ARP200101749 A AR P200101749A AR P200101749 A ARP200101749 A AR P200101749A AR 119210 A1 AR119210 A1 AR 119210A1
Authority
AR
Argentina
Prior art keywords
pyrrolo
fluoro
indazol
thiazol
imidazol
Prior art date
Application number
ARP200101749A
Other languages
English (en)
Inventor
Cosimo Dolente
Annick Goergler
David Stephen Hewings
Georg Jaeschke
Bernd Kuhn
Yvonne Alice Nagel
Christa Ulrike Obst-Sander
Antonio Ricci
Daniel Rueher
Sandra Steiner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR119210A1 publication Critical patent/AR119210A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compuestos derivados de pirrolo[1,2-c]imidazol como inhibidores allostéricos de EGFR, composición farmacéutica que los comprende y su uso en el tratamiento del cáncer de pulmón no microcítico. Reivindicación 1: Un compuesto seleccionado entre 2-((R)-6-fluoro-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-2-(4-fluoro-6-(3-fluoro-4-morfolinofenil)-2H-indazol-2-il)-N-(tiazol-2-il)acetamida; 2-(4-cloro-7-fluoro-6-(4-morfolinofenil)-2H-indazol-2-il)-2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-N-(tiazol-2-il)acetamida; 2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-2-(4-fluoro-6-(3-fluoro-4-morfolinofenil)-2H-indazol-2-il)-N-(tiazol-2-il)acetamida; 2-(4,7-dicloro-6-(4-morfolinofenil)-2H-indazol-2-il)-2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-N-(tiazol-2-il)acetamida; 2-(4-cloro-7-fluoro-6-(3-fluoro-4-morfolinofenil)-2H-indazol-2-il)-2-(6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il)-N-(tiazol-2-il)acetamida; 2-[4-cloro-7-metoxi-6-(4-morfolin-4-ilfenil)indazol-2-il]-2-[rac-(6R)-6-fluoro-6,7-dihidro-5H-pirrolo[1,2-c]imidazol-1-il]-N-(1,3-tiazol-2-il)acetamida; o sales farmacéuticamente aceptables.
ARP200101749A 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR AR119210A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP19181754 2019-06-21

Publications (1)

Publication Number Publication Date
AR119210A1 true AR119210A1 (es) 2021-12-01

Family

ID=67139601

Family Applications (4)

Application Number Title Priority Date Filing Date
ARP200101747A AR119208A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
ARP200101745A AR119206A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
ARP200101749A AR119210A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
ARP200101748A AR119209A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ARP200101747A AR119208A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
ARP200101745A AR119206A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP200101748A AR119209A1 (es) 2019-06-21 2020-06-19 DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR

Country Status (28)

Country Link
US (4) US20230054473A1 (es)
EP (4) EP3986896B1 (es)
JP (4) JP2022538403A (es)
KR (1) KR20220024105A (es)
CN (4) CN113993873A (es)
AR (4) AR119208A1 (es)
AU (1) AU2020295703A1 (es)
BR (1) BR112021025445B1 (es)
CA (1) CA3140485A1 (es)
CL (1) CL2021003408A1 (es)
CO (1) CO2021017173A2 (es)
CR (1) CR20210624A (es)
DK (1) DK3986897T3 (es)
ES (1) ES2961187T3 (es)
FI (1) FI3986897T3 (es)
HR (1) HRP20231276T1 (es)
HU (1) HUE063676T2 (es)
IL (1) IL288522A (es)
LT (1) LT3986897T (es)
MA (1) MA56508B1 (es)
MX (1) MX2021015464A (es)
PE (1) PE20220576A1 (es)
PL (1) PL3986897T3 (es)
PT (1) PT3986897T (es)
RS (1) RS64720B1 (es)
SI (1) SI3986897T1 (es)
TW (4) TW202115074A (es)
WO (4) WO2020254562A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023217923A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag New indazole derivatives
WO2023217924A1 (en) * 2022-05-13 2023-11-16 F. Hoffmann-La Roche Ag Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0508715D0 (en) * 2005-04-29 2005-06-08 Astrazeneca Ab Chemical compounds
CN101273033A (zh) * 2005-09-20 2008-09-24 阿斯利康(瑞典)有限公司 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-（1h-吲哚-5-基-氨基）-喹唑啉化合物
JP2011525927A (ja) 2008-06-25 2011-09-29 シェーリング コーポレイション 複素環式抗菌剤の合成および使用
US8420661B2 (en) 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
WO2015095807A1 (en) * 2013-12-20 2015-06-25 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of egfr and erk inhibitors
CN105777756B (zh) * 2014-07-02 2019-03-01 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
CN107108613B (zh) * 2014-11-10 2020-02-25 基因泰克公司 布罗莫结构域抑制剂及其用途
SG11201708820TA (en) 2015-05-14 2017-11-29 Wistar Inst Ebna1 inhibitors and methods using same
TW201834651A (zh) * 2016-12-22 2018-10-01 瑞士商赫孚孟拉羅股份公司 化合物
WO2018220149A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Compounds
WO2019046668A1 (en) * 2017-08-31 2019-03-07 Kezar Life Sciences AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN
CR20200625A (es) * 2018-06-29 2021-02-05 Hoffmann La Roche Compuestos

Also Published As

Publication number Publication date
KR20220024105A (ko) 2022-03-03
TW202115071A (zh) 2021-04-16
US20220315592A1 (en) 2022-10-06
AR119208A1 (es) 2021-12-01
WO2020254572A1 (en) 2020-12-24
HRP20231276T1 (hr) 2024-02-02
AR119206A1 (es) 2021-12-01
AR119209A1 (es) 2021-12-01
EP3986896A1 (en) 2022-04-27
EP3986898A1 (en) 2022-04-27
EP3986895B1 (en) 2023-03-15
CA3140485A1 (en) 2020-12-24
US20220135571A1 (en) 2022-05-05
BR112021025445B1 (pt) 2024-02-27
LT3986897T (lt) 2023-11-10
AU2020295703A1 (en) 2022-01-06
RS64720B1 (sr) 2023-11-30
SI3986897T1 (sl) 2023-12-29
BR112021025445A2 (pt) 2022-02-01
CN113993872A (zh) 2022-01-28
WO2020254565A1 (en) 2020-12-24
JP2022538055A (ja) 2022-08-31
US20230054473A1 (en) 2023-02-23
CL2021003408A1 (es) 2022-10-14
EP3986896B1 (en) 2023-03-15
CO2021017173A2 (es) 2022-01-17
JP2022537191A (ja) 2022-08-24
WO2020254562A1 (en) 2020-12-24
CN113966335A (zh) 2022-01-21
ES2961187T3 (es) 2024-03-08
CN113993873A (zh) 2022-01-28
TW202115074A (zh) 2021-04-16
JP2022537769A (ja) 2022-08-29
JP2022538403A (ja) 2022-09-02
PL3986897T3 (pl) 2024-01-22
CN114008049A (zh) 2022-02-01
PE20220576A1 (es) 2022-04-20
DK3986897T3 (da) 2023-10-30
EP3986897B1 (en) 2023-08-30
TW202115053A (zh) 2021-04-16
CR20210624A (es) 2022-02-14
TW202115072A (zh) 2021-04-16
IL288522A (en) 2022-01-01
MX2021015464A (es) 2022-01-24
EP3986898B1 (en) 2023-03-15
EP3986895A1 (en) 2022-04-27
US20220315593A1 (en) 2022-10-06
HUE063676T2 (hu) 2024-01-28
FI3986897T3 (fi) 2023-10-20
WO2020254568A1 (en) 2020-12-24
MA56508A (fr) 2022-04-27
PT3986897T (pt) 2023-10-23
EP3986897A1 (en) 2022-04-27
MA56508B1 (fr) 2023-11-30

Similar Documents

Publication Publication Date Title
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
NZ766835A (en) Pharmaceutical compounds
CL2019002150A1 (es) Derivados de 3-fenil-4-amino-imidazo[4,5-c]piridin-2-ona y 7-fenil-6-amino-purin-8-ona sustituidos, inhibidores de tirosinacinasas, en particular tirosinacinasa de bruton (btk); composiciones que contiene los compuestos; y uso para enfermedades tales como cáncer, autoinmunitarias, inflamatorias y tromboembólicas. (divisional solicitud 201703073)
EA201790122A1 (ru) Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение
UY30298A1 (es) Inhibidores de la quinasa c-fms ii
CO2017011038A2 (es) Derivados de (s)-2-((2-oxooxazolidin-3-il)-5,6-dihidrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-il)amino)amidas como inhibidores de pi3kca”
AR060631A1 (es) Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k)
NI201000004A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
NI201000003A (es) Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas.
DOP2018000065A (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm) para el tratamiento del cáncer
EA200970595A1 (ru) Производные замещенных индазолов, активные в качестве ингибиторов киназ
CO7240408A2 (es) Formas cristalinas de un inhibidor de tirosina quinasa de bruton
CO6251364A2 (es) Derivados de morfolino pirimidina utilazdos en enfermedades relacionados con mtor quinasa y/o p13k
PE20150637A1 (es) Derivados de pirrolotriazinona como inhibidores de pi3k
PA8622801A1 (es) Derivados 1h-tieno(2,3-c)pirazol utiles como inhibidores de quinasa
GT200900056A (es) Benzoxazoles y oxazolopiridinas utiles como inhibidores de la quinasa janus
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
AR119210A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
PE20211805A1 (es) Formulaciones de un inhibidor de axl/mer
UY31866A (es) Combinaciones farmacéuticas comprendiendo los compuestos 3-z[1-(4-(n-((4-metil-piperazin-1-il)-metilcarbonil)-n-metil-amino)-anilino)-1-fenil-metilene]-6-metoxicarbonil-2-indolinona y el ácido n-[4-[2-(2-amino-4,7-dihidro-4-oxo-1h-pirrolo [2,3-d] pirimidin-5-il)etil]benzoil]-l-glutamico; sus sales farmacéuticamente aceptables y aplicaciones
BR112022005729A2 (pt) Compostos de pirazolopiridina como inibidores seletivos da quinase de btk
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
AR119207A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
MX2017011423A (es) Derivados de 7-(morfolin-4-il)pirazolo[1,5-a]pirimidina que son utiles para el tratamiento de enfermedades inmunes o inflamatorias o cancer.